AR093818A1 - Compuesto de 1-(bencil sustituido)piperazina sustituida - Google Patents
Compuesto de 1-(bencil sustituido)piperazina sustituidaInfo
- Publication number
- AR093818A1 AR093818A1 ARP130104518A ARP130104518A AR093818A1 AR 093818 A1 AR093818 A1 AR 093818A1 AR P130104518 A ARP130104518 A AR P130104518A AR P130104518 A ARP130104518 A AR P130104518A AR 093818 A1 AR093818 A1 AR 093818A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- group
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto de 1-(bencil sustituido)piperazina sustituida, o una de sus sales farmacéuticamente aceptables, que es de la fórmula (1) en donde: R¹ es: alquilo C₁₋₆; metilo sustituido con i) cicloalquilo C₃₋₅; ii) fenoxi; o iii) un fenilo y un segundo sustituyente seleccionado del grupo que consiste en: metilo halo y metoxi; etilo sustituido con i) fenilo, dicho fenilo está opcionalmente sustituido con halo o metoxi o ii) heteroarilo; bencilo, en donde el grupo fenilo de dicho bencilo está opcionalmente sustituido con halo, metoxi o SO₂CH₂CH₃; alquenilo C₂ opcionalmente sustituido con un F y un fenilo; cicloalquilo C₃₋₇, dicho cicloalquilo está opcionalmente sustituido con uno o dos sustituyentes seleccionados del grupo que consiste en fenilo, metilo y F; o dicho cicloalquilo está opcionalmente fusionado con un anillo fenilo; heterocicloalquilo opcionalmente sustituido con uno o dos alquilo C₁₋₃; heteroarilo opcionalmente sustituido con uno a dos sustituyentes seleccionados del grupo que consiste en: alquilo C₁₋₃, alcoxi C₁₋₃ y CF₃; y fenilo sustituido con uno a tres sustituyentes seleccionados del grupo que consiste en: i) halo; ii) CN; iii) alquilo C₁₋₃ opcionalmente sustituido con uno a tres F; iv) alcoxi C₁₋₃; v) (CH₂)ₙNRᵃRᵇ; vi) C(O)CH₃; y vii) CH₂OCH₃; R² es halo o alquilo C₁₋₃; R³ es halo o metilo; R⁴ es H o metilo; R⁵ es alquilo C₁₋₃; R⁶ es alquilo C₁₋₃; R⁷ está seleccionado del grupo que consiste en: alquilo C₁₋₇ opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halo, cicloalquilo C₃₋₅ y CF₃; cicloalquilo C₃₋₇ opcionalmente sustituido con uno o dos sustituyentes seleccionados del grupo que consiste en F, CH₂F, CHF₂, metilo y metoxi; cada k es 0 ó 1; cada p 0 ó 1; cada n es 0, 1 ó 2; cada Rᵃ es H o alquilo C₁₋₃; cada Rᵇ es H o alquilo C₁₋₃; siempre que: (i) R⁷ no sea fenilo cuando R¹ es piperazinilo; y ii) R⁷ no sea clorofenilo cuando R¹ es fenilo. Estos compuestos son moduladores del receptor huérfano g relacionado con retinoides (RORg) y se emplean en el tratamiento de enfermedades mediadas por RORg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012001636 | 2012-12-06 | ||
| CN2013000182 | 2013-02-25 | ||
| CN2013000803 | 2013-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093818A1 true AR093818A1 (es) | 2015-06-24 |
Family
ID=49709687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104518A AR093818A1 (es) | 2012-12-06 | 2013-12-05 | Compuesto de 1-(bencil sustituido)piperazina sustituida |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US10005731B2 (es) |
| EP (2) | EP3219711A1 (es) |
| JP (1) | JP6279605B2 (es) |
| KR (1) | KR20150092244A (es) |
| CN (1) | CN105121430B (es) |
| AR (1) | AR093818A1 (es) |
| AU (1) | AU2013354109B2 (es) |
| BR (1) | BR112015013137B1 (es) |
| CA (1) | CA2894016C (es) |
| CL (1) | CL2015001557A1 (es) |
| CR (1) | CR20150302A (es) |
| CY (1) | CY1118932T1 (es) |
| DK (1) | DK2928885T3 (es) |
| EA (1) | EA026437B1 (es) |
| ES (1) | ES2626390T3 (es) |
| HK (1) | HK1214814A1 (es) |
| HR (1) | HRP20170638T1 (es) |
| HU (1) | HUE033212T2 (es) |
| IL (1) | IL239082A0 (es) |
| LT (1) | LT2928885T (es) |
| ME (1) | ME02696B (es) |
| MX (1) | MX2015007180A (es) |
| PE (1) | PE20151144A1 (es) |
| PH (1) | PH12015501244A1 (es) |
| PL (1) | PL2928885T3 (es) |
| PT (1) | PT2928885T (es) |
| RS (1) | RS55875B1 (es) |
| SG (1) | SG11201504200TA (es) |
| SI (1) | SI2928885T1 (es) |
| TW (1) | TW201427959A (es) |
| UY (1) | UY35174A (es) |
| WO (1) | WO2014086894A1 (es) |
| ZA (1) | ZA201503666B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3027616B1 (en) * | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| PE20161372A1 (es) | 2014-02-03 | 2017-01-08 | Vitae Pharmaceuticals Inc | Inhibidores de dihidropirrolopiridina de ror-gamma |
| PE20170137A1 (es) | 2014-05-28 | 2017-03-05 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos |
| EP3148975B1 (en) * | 2014-05-28 | 2018-11-28 | GlaxoSmithKline Intellectual Property Development Limited | Piperazine derivatives as ror-gamma modulators |
| CN106660999A (zh) | 2014-05-28 | 2017-05-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
| CN104292208A (zh) * | 2014-09-09 | 2015-01-21 | 上海师范大学 | 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法 |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| UA118989C2 (uk) | 2014-10-14 | 2019-04-10 | Вітае Фармасьютікалс, Інк. | Дигідропіролопіридинові інгібітори ror-гамма |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| TW201625588A (zh) * | 2014-11-05 | 2016-07-16 | 第一三共股份有限公司 | 環狀胺衍生物 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2016120849A1 (en) * | 2015-01-30 | 2016-08-04 | Pfizer Inc. | Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| RU2771280C2 (ru) * | 2016-07-13 | 2022-04-29 | Лео Фарма А/С | Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма |
| CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
| JP6737967B1 (ja) * | 2017-07-18 | 2020-08-12 | ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ | ５−フルオロ−２−メチル−３−ニトロ安息香酸およびそのメチルエステルを製造する方法 |
| CN111225914B (zh) | 2017-07-24 | 2022-10-11 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN108752185A (zh) * | 2018-07-17 | 2018-11-06 | 成都道合尔医药技术有限公司 | 一种1-氟-环戊甲酸的合成方法 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| CN110862319A (zh) * | 2019-12-04 | 2020-03-06 | 深圳振强生物技术有限公司 | 奥扎格雷杂质的制备方法 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078839A2 (en) * | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| BR112013027670B1 (pt) | 2011-04-28 | 2021-11-09 | Japan Tobacco Inc | Composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory |
| US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| BR112014005268A2 (pt) | 2011-09-09 | 2017-03-28 | Univ New York | compostos de amido como moduladores de ror t e usos dos mesmos |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| US9428452B2 (en) | 2012-04-27 | 2016-08-30 | Glaxo Group Limited | Compounds |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2015061686A2 (en) | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
| CA2928537A1 (en) | 2013-10-25 | 2015-04-30 | Glaxosmithkline Llc | Novel compounds |
| CN106660999A (zh) | 2014-05-28 | 2017-05-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
| EP3148975B1 (en) | 2014-05-28 | 2018-11-28 | GlaxoSmithKline Intellectual Property Development Limited | Piperazine derivatives as ror-gamma modulators |
| PE20170137A1 (es) | 2014-05-28 | 2017-03-05 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos |
-
2013
- 2013-12-05 US US14/649,585 patent/US10005731B2/en active Active
- 2013-12-05 JP JP2015546002A patent/JP6279605B2/ja active Active
- 2013-12-05 CN CN201380070619.3A patent/CN105121430B/zh active Active
- 2013-12-05 AU AU2013354109A patent/AU2013354109B2/en not_active Ceased
- 2013-12-05 LT LTEP13799318.4T patent/LT2928885T/lt unknown
- 2013-12-05 EP EP17157475.9A patent/EP3219711A1/en not_active Withdrawn
- 2013-12-05 EP EP13799318.4A patent/EP2928885B1/en active Active
- 2013-12-05 KR KR1020157017633A patent/KR20150092244A/ko not_active Application Discontinuation
- 2013-12-05 PT PT137993184T patent/PT2928885T/pt unknown
- 2013-12-05 CA CA2894016A patent/CA2894016C/en active Active
- 2013-12-05 WO PCT/EP2013/075594 patent/WO2014086894A1/en active Application Filing
- 2013-12-05 SG SG11201504200TA patent/SG11201504200TA/en unknown
- 2013-12-05 AR ARP130104518A patent/AR093818A1/es unknown
- 2013-12-05 MX MX2015007180A patent/MX2015007180A/es unknown
- 2013-12-05 UY UY0001035174A patent/UY35174A/es unknown
- 2013-12-05 PL PL13799318T patent/PL2928885T3/pl unknown
- 2013-12-05 ES ES13799318.4T patent/ES2626390T3/es active Active
- 2013-12-05 RS RS20170372A patent/RS55875B1/sr unknown
- 2013-12-05 EA EA201591059A patent/EA026437B1/ru not_active IP Right Cessation
- 2013-12-05 TW TW102144579A patent/TW201427959A/zh unknown
- 2013-12-05 DK DK13799318.4T patent/DK2928885T3/en active
- 2013-12-05 PE PE2015000712A patent/PE20151144A1/es not_active Application Discontinuation
- 2013-12-05 BR BR112015013137-9A patent/BR112015013137B1/pt active IP Right Grant
- 2013-12-05 HU HUE13799318A patent/HUE033212T2/hu unknown
- 2013-12-05 ME MEP-2017-117A patent/ME02696B/me unknown
- 2013-12-05 SI SI201330650A patent/SI2928885T1/sl unknown
-
2015
- 2015-05-22 ZA ZA2015/03666A patent/ZA201503666B/en unknown
- 2015-05-28 IL IL239082A patent/IL239082A0/en unknown
- 2015-06-02 PH PH12015501244A patent/PH12015501244A1/en unknown
- 2015-06-05 CL CL2015001557A patent/CL2015001557A1/es unknown
- 2015-06-08 CR CR20150302A patent/CR20150302A/es unknown
-
2016
- 2016-03-09 HK HK16102705.4A patent/HK1214814A1/zh not_active IP Right Cessation
-
2017
- 2017-04-24 HR HRP20170638TT patent/HRP20170638T1/hr unknown
- 2017-06-02 CY CY20171100587T patent/CY1118932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR090847A1 (es) | Compuestos moduladores del receptor huerfano retinoideo (ror) | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR102977A1 (es) | Inhibidores de erk | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR103412A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR106138A1 (es) | Compuestos y métodos para inhibir jak | |
| AR093921A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x7 | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR100439A1 (es) | Derivados de carboxamida | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| AR080703A1 (es) | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |